AU2002244946A1 - Drugs containing genetically modified antibody against ganglioside GD3 - Google Patents
Drugs containing genetically modified antibody against ganglioside GD3Info
- Publication number
- AU2002244946A1 AU2002244946A1 AU2002244946A AU2002244946A AU2002244946A1 AU 2002244946 A1 AU2002244946 A1 AU 2002244946A1 AU 2002244946 A AU2002244946 A AU 2002244946A AU 2002244946 A AU2002244946 A AU 2002244946A AU 2002244946 A1 AU2002244946 A1 AU 2002244946A1
- Authority
- AU
- Australia
- Prior art keywords
- genetically modified
- antibody against
- modified antibody
- drugs containing
- containing genetically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- LHWDRTXZYZBFET-YBFHIOIGSA-N (2S,4S,5R,6R)-5-acetamido-6-[(1S,2R)-2-[(2S,4S,5R,6R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6R)-6-[(E,2S,3R)-2-formamido-3-hydroxyoctadec-4-enoxy]-4,5-dihyd Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC=O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@@H](CO)O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@@H](O)[C@@H](CO)O1 LHWDRTXZYZBFET-YBFHIOIGSA-N 0.000 title 1
- 102000004965 antibodies Human genes 0.000 title 1
- 108090001123 antibodies Proteins 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drugs Drugs 0.000 title 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001-97483 | 2001-03-29 | ||
| JP2001097483 | 2001-03-29 | ||
| PCT/JP2002/003170 WO2002078739A1 (en) | 2001-03-29 | 2002-03-29 | Drugs containing genetically modified antibody against ganglioside gd3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002244946A1 true AU2002244946A1 (en) | 2003-04-03 |
| AU2002244946B2 AU2002244946B2 (en) | 2007-05-10 |
Family
ID=18951264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002244946A Ceased AU2002244946B2 (en) | 2001-03-29 | 2002-03-29 | Drugs containing genetically modified antibody against ganglioside GD3 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20050260206A1 (en) |
| EP (1) | EP1384487A4 (en) |
| JP (1) | JPWO2002078739A1 (en) |
| AU (1) | AU2002244946B2 (en) |
| CA (1) | CA2441863A1 (en) |
| WO (1) | WO2002078739A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2002078739A1 (en) * | 2001-03-29 | 2004-07-22 | 協和醗酵工業株式会社 | Pharmaceutical containing a recombinant antibody against ganglioside GD3 |
| WO2005053742A1 (en) * | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicine containing antibody composition |
| US20070003557A1 (en) * | 2005-04-21 | 2007-01-04 | Andres Forero | Method for treating cancer using premedication |
| EP1918304A1 (en) * | 2006-11-02 | 2008-05-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II) |
| US20110256147A1 (en) * | 2008-12-01 | 2011-10-20 | The Johns Hopkins University | Diagnostic and treatment methods for cancer based on immune inhibitors |
| WO2012024287A1 (en) | 2010-08-17 | 2012-02-23 | Allergan, Inc. | Method of stabilizing and sterilizing peptides or proteins |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1339798C (en) * | 1985-02-01 | 1998-04-07 | Alan N. Houghton | Method for treatment of neuroectodermal malignancies and epithelial carcinomas in humans |
| EP0267615A3 (en) * | 1986-11-13 | 1989-05-03 | Sloan-Kettering Institute For Cancer Research | Compositions and method for treatment of cancer using monoclonal antibody against gd3 ganglioside together with il-2 |
| CA2078539C (en) * | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
| WO1999043815A2 (en) * | 1998-02-27 | 1999-09-02 | Novopharm Biotech Inc. | Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof |
| DE60038252T2 (en) * | 1999-09-30 | 2009-03-19 | Kyowa Hakko Kogyo Co., Ltd. | Human antibody against ganglioside GD3 for the transplantation completeity determining region and derivatives of the anti-ganglioside GD3 antibody |
| JPWO2002078739A1 (en) * | 2001-03-29 | 2004-07-22 | 協和醗酵工業株式会社 | Pharmaceutical containing a recombinant antibody against ganglioside GD3 |
-
2002
- 2002-03-29 JP JP2002577004A patent/JPWO2002078739A1/en active Pending
- 2002-03-29 WO PCT/JP2002/003170 patent/WO2002078739A1/en not_active Application Discontinuation
- 2002-03-29 EP EP02713258A patent/EP1384487A4/en not_active Withdrawn
- 2002-03-29 AU AU2002244946A patent/AU2002244946B2/en not_active Ceased
- 2002-03-29 US US10/473,037 patent/US20050260206A1/en not_active Abandoned
- 2002-03-29 CA CA002441863A patent/CA2441863A1/en not_active Abandoned
-
2008
- 2008-02-19 US US12/033,516 patent/US20080166345A1/en not_active Abandoned
-
2009
- 2009-04-08 US US12/420,142 patent/US20090226399A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU7912100A (en) | Pharmaceutical composition comprising an antigen | |
| AU2002303164A1 (en) | Fatty amine drug conjugates | |
| AU2002315779A1 (en) | Soft capsules | |
| IL207028A0 (en) | Pharmaceutical nati-tnf-alpha antibody formulation | |
| AU2002365120A1 (en) | Medicaments | |
| HK1068812A1 (en) | Drug preparations | |
| AU2002226211A1 (en) | Individualized anti-cancer antibodies | |
| AU2002332197A1 (en) | Nicotine-containing film preparation | |
| AUPR395801A0 (en) | Antibodies against cancer | |
| AU2002365649A1 (en) | Anti-dota antibody | |
| AU2002214006A1 (en) | Drugs for diabetes | |
| AU2002307438A1 (en) | Cancer-testis antigens | |
| AU6278300A (en) | Tumor-associated antigen (r11) | |
| AU2002244946A1 (en) | Drugs containing genetically modified antibody against ganglioside GD3 | |
| AU2002251448A1 (en) | Oral absorbed drugs | |
| AU2002333276A1 (en) | Drugs for vasculopaties | |
| AU2001292301A1 (en) | Novel drugs for liver diseases | |
| AU7449200A (en) | Derivatives of antibody against ganglioside gm2 | |
| AU2001297710A1 (en) | Integrated drug development techniques | |
| AU2002342940A1 (en) | New pharmaceutical compounds | |
| AU2002361450A1 (en) | Novel pharmaceutical | |
| AU2001232068A1 (en) | Delivery capsules | |
| AUPR738001A0 (en) | Compound for medicinal purposes | |
| AU2002251537A1 (en) | Medicines | |
| AU2002238979A1 (en) | Drugs containing reduced vitamin b2 |